CL2017002593A1 - Tableta de ribociclib. - Google Patents

Tableta de ribociclib.

Info

Publication number
CL2017002593A1
CL2017002593A1 CL2017002593A CL2017002593A CL2017002593A1 CL 2017002593 A1 CL2017002593 A1 CL 2017002593A1 CL 2017002593 A CL2017002593 A CL 2017002593A CL 2017002593 A CL2017002593 A CL 2017002593A CL 2017002593 A1 CL2017002593 A1 CL 2017002593A1
Authority
CL
Chile
Prior art keywords
ribociclib
tablet
coated
directed
present disclosure
Prior art date
Application number
CL2017002593A
Other languages
English (en)
Inventor
Arnaud Grandeury
Bindhumadhavan Gururajan
Rui Costa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002593(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017002593A1 publication Critical patent/CL2017002593A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente descripción está dirigida al comprimido oral de ribociclib incluyendo su(s) sal(es), Una forma de realización de la presente descripción se dirige al comprimido de ribociclib con alta carga de fármaco con un perfil de liberación inmediata, Una realización de la presente descripción se refiere a un comprimido de ribociclib recubierto. Otra realización de la presente descripción se refiera a un comprimido de ribociclib recubierto donde el rebestimiento es una avanzada barrera contra la humedad (por ejemplo, el recubrimiento OPABRY amb II d3nde el recubrimiento de basa en PVA).</p>
CL2017002593A 2015-04-16 2017-10-13 Tableta de ribociclib. CL2017002593A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16

Publications (1)

Publication Number Publication Date
CL2017002593A1 true CL2017002593A1 (es) 2018-05-18

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002593A CL2017002593A1 (es) 2015-04-16 2017-10-13 Tableta de ribociclib.

Country Status (31)

Country Link
US (6) US10799506B2 (es)
EP (3) EP4197530B1 (es)
JP (1) JP2018514523A (es)
KR (2) KR102750931B1 (es)
CN (2) CN107530292B (es)
AR (1) AR104257A1 (es)
AU (5) AU2016248017A1 (es)
BR (1) BR112017021283A2 (es)
CA (1) CA2982425C (es)
CL (1) CL2017002593A1 (es)
CO (1) CO2017010510A2 (es)
DK (2) DK3283058T3 (es)
EA (1) EA201792290A1 (es)
EC (1) ECSP17075052A (es)
ES (2) ES3062263T3 (es)
FI (2) FI3283058T3 (es)
HR (2) HRP20230053T1 (es)
HU (1) HUE061213T2 (es)
IL (1) IL254818A0 (es)
LT (1) LT4197530T (es)
MX (1) MX2017013350A (es)
PE (1) PE20180035A1 (es)
PH (1) PH12017501820A1 (es)
PL (2) PL3283058T3 (es)
PT (2) PT3283058T (es)
RS (1) RS67697B1 (es)
SG (1) SG11201708084PA (es)
SI (2) SI3283058T1 (es)
TN (1) TN2017000422A1 (es)
TW (1) TW201642864A (es)
WO (1) WO2016166703A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105828822B (zh) 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
CN107530292B (zh) * 2015-04-16 2022-11-01 诺华股份有限公司 瑞博西尼片剂
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Crystalline form of ribociclib succinate
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
CN118652252A (zh) 2019-12-16 2024-09-17 卢内拉生物技术有限公司 选择性cdk4/6抑制剂型癌症治疗药物
AU2020405427B2 (en) 2019-12-16 2025-01-09 Lunella Biotech, Inc. Selective CDK4/6 inhibitor cancer therapeutics
US20230310327A1 (en) * 2020-08-03 2023-10-05 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
MX2022015336A (es) * 2020-09-29 2023-01-11 Laboratorios Silanes S A De C V Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares.
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
CN120112291A (zh) 2022-08-31 2025-06-06 阿尔维纳斯运营股份有限公司 雌激素受体降解剂的给药方案
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
CN121358477A (zh) 2023-03-27 2026-01-16 诺华股份有限公司 使用瑞波西利与芳香化酶抑制剂组合治疗早期乳腺癌的方法
TW202602868A (zh) 2024-04-15 2026-01-16 瑞士商諾華公司 瑞波西利的藥物組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
US8784781B2 (en) * 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
LT2872482T (lt) * 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
US9867825B2 (en) * 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
MA38522A1 (fr) * 2013-03-21 2017-10-31 Novartis Ag Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
CN107530292B (zh) 2015-04-16 2022-11-01 诺华股份有限公司 瑞博西尼片剂
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
LT4197530T (lt) 2026-02-25
PT3283058T (pt) 2023-02-03
CA2982425C (en) 2023-10-31
AU2020250190A1 (en) 2020-11-05
EP3283058A1 (en) 2018-02-21
HRP20230053T1 (hr) 2023-03-03
US20250134893A1 (en) 2025-05-01
PH12017501820A1 (en) 2018-04-23
EP4620458A2 (en) 2025-09-24
CA2982425A1 (en) 2016-10-20
AU2024227794A1 (en) 2024-11-21
TW201642864A (zh) 2016-12-16
PE20180035A1 (es) 2018-01-09
IL254818A0 (en) 2017-12-31
KR20250009572A (ko) 2025-01-17
AU2016248017A1 (en) 2017-10-19
US10799506B2 (en) 2020-10-13
HUE061213T2 (hu) 2023-05-28
EP3283058B1 (en) 2022-11-16
SI3283058T1 (sl) 2023-03-31
PT4197530T (pt) 2026-02-05
ES3062263T3 (en) 2026-04-09
CN115554257A (zh) 2023-01-03
BR112017021283A2 (pt) 2018-06-26
US20200390771A1 (en) 2020-12-17
WO2016166703A1 (en) 2016-10-20
CN107530292A (zh) 2018-01-02
FI4197530T3 (fi) 2026-02-03
US20250090531A1 (en) 2025-03-20
SI4197530T1 (sl) 2026-03-31
US20250127785A1 (en) 2025-04-24
KR20170137101A (ko) 2017-12-12
AR104257A1 (es) 2017-07-05
SG11201708084PA (en) 2017-10-30
KR102750931B1 (ko) 2025-01-09
PL3283058T3 (pl) 2023-03-20
ES2938261T3 (es) 2023-04-05
AU2022215155B2 (en) 2024-08-01
MX2017013350A (es) 2018-01-25
AU2022215155A1 (en) 2022-09-01
AU2019201929B2 (en) 2020-07-09
FI3283058T3 (fi) 2023-03-01
AU2019201929A1 (en) 2019-04-11
HRP20260123T1 (hr) 2026-03-13
EP4197530A1 (en) 2023-06-21
EP4620458A3 (en) 2025-10-22
EP4197530B1 (en) 2025-11-12
US12064434B2 (en) 2024-08-20
CO2017010510A2 (es) 2018-03-20
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
ECSP17075052A (es) 2018-02-28
US20230104792A1 (en) 2023-04-06
TN2017000422A1 (en) 2019-01-16
DK3283058T3 (da) 2023-02-13
JP2018514523A (ja) 2018-06-07
PL4197530T3 (pl) 2026-03-23
RS67697B1 (sr) 2026-02-27
CN107530292B (zh) 2022-11-01
EA201792290A1 (ru) 2018-02-28
DK4197530T3 (da) 2026-02-09

Similar Documents

Publication Publication Date Title
CL2017002593A1 (es) Tableta de ribociclib.
BR112016013502A2 (pt) unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol.
EP3652650A4 (en) TECHNIQUES FOR MANAGING ACCESS TO A HARDWARE ACCELERATOR MEMORY
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
BR112015032445A2 (pt) componente semicondutor orgânico
EP2986681A4 (en) An aqueous coating composition
EP4349406A3 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
PT2989110T (pt) Derivados de tamoxifeno para o tratamento de doenças neoplásicas, especialmente com nível elevado de proteína her2
AR098168A1 (es) Formulación estable de insulina glulisina
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CU20180014A7 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
MX2017002633A (es) Composicion polimerica para capa de elemento de capa.
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
DK3844161T3 (da) Heteroaromatiske forbindelser som vanininhibitorer.
BR112016007410A2 (pt) liberação lenta de conjugados de sn 38
UA117833C2 (uk) Склад з відстроченим вивільненням, що містить гранули цистеаміну, і способи його одержання та застосування
EA201890828A1 (ru) Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин
EP3231017A4 (en) Laser stop layer for foil-based metallization of solar cells
EP3274832A4 (en) Byte level granularity buffer overflow detection for memory corruption detection architectures
EP3296615A4 (en) Embedded light source encapsulation structure
BR112018070547A2 (pt) agonistas de rara para o tratamento de aml e mds
CL2016000719A1 (es) Un sistema para el recubrimiento de lentes ópticos, que comprende: una carcasa que tiene al menos dos caras a través de la cual se forma una abertura; y un soporte de lente que tiene una apertura del lente que acepta un lente óptico y que tiene una forma exterior y tamaño que es complementario y está aceptado dentro de la abertura de la carcasa.
GB2543709A (en) Pharmaceutical agent
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona